portfolio strategy

Top oncology breakthroughs shared at ESMO 2021

Clarivate oncology experts share major takeaways from ESMO and their expected impact on the treatment landscape and patients. As part of our Drugs to Watch™ series, which reviews therapies expected to have significant impact on healthcare markets, Clarivate oncology experts sifted through the more than 2,800 abstracts that were accepted for presentation at the ESMO […]

Type 2 diabetes in Mainland China: Shifting treatment patterns

Mainland China has gone through a series of regulatory and reimbursement reforms in recent years in an effort to keep pace with its dynamic economic and demographic landscape. Clarivate market assessment expert Karan Verma discusses the role of these reforms in Mainland China’s type 2 diabetes market and how they could broaden access to innovative […]

Volume-Based Procurement in Mainland China: Key trends and planning future strategies

Mainland China has gone through a series of regulatory and reimbursement reforms in recent years in an effort to keep pace with its dynamic economic and demographic landscape. Clarivate expert Karan Verma discusses how the Volume-Based Procurement program is transforming the generics landscape, increasing patient access and prompting manufactures to rethink strategies.   Remodeling Mainland […]

Paradigm-changing primary Phase III data for malignant melanoma: What to expect from Relatlimab in combination with Opdivo

Bristol’s Relatlimab/Opdivo (anti-LAG-3/PD-1) therapy is poised to make inroads into its own Opdivo/Yervoy (PD-1/CTLA-4) inhibitor combination share for malignant melanoma. As part of our Drugs to Watch™ series, Clarivate oncology experts Liseth Parra and Rachel Webster review new data shared at ASCO 2021, and implications for patients and life sciences companies.   Compelling Phase III […]

KEYNOTE-564 paves future role for immunotherapy in adjuvant renal cell carcinoma

Merck &Co.’s Keytruda has practice-changing potential as adjuvant therapy for renal cell carcinoma. As part of our Drugs to Watch™ series, Clarivate oncology experts Priyanka Mehra and Sorcha Cassidy review new data shared at the 2021 ASCO Annual Meeting, and implications for patients and life sciences companies.   The renal cell carcinoma treatment landscape continues […]

The evolution of the asset-centric approach in biotech venture capital

In this episode of Conversations in Healthcare, Mike Ward speaks with Francesco De Rubertis, co-founder and managing partner at Medicxi, about the evolution of the biotech venture capital model and the emergence of the asset-centric approach.   Mike Ward: I’m delighted to be joined by Francesco De Rubertis, a co-founder and managing partner at Medicxi, […]

Roche’s Tecentriq shows promise in resectable NSCLC: key takeaways for the market

Tecentriq, Roche’s flagship anti-PD-L1 therapy, gets one step closer to becoming the first immunotherapy to gain approval as adjuvant therapy in resectable non-small cell lung cancer (NSCLC). As part of our Drugs to Watch™ series, Clarivate oncology experts Arman Esfandiari, Amardeep Singh and Khurram Nawaz review new data shared at ASCO 2021, and implications for […]

Six oncology breakthroughs from Mainland China: Takeaways from ASCO 2021

Clarivate oncology experts analyzed ASCO 2021 abstracts from Mainland China to highlight key trends and breakthrough treatments that are expected to impact the oncology landscape. Mainland Chinese companies were strongly represented at the 2021 ASCO Annual Meeting. As part of our Drugs to Watch™ series spotlighting therapies expected to have significant impact on drug landscapes, […]

10 takeaways from the Clarivate Innovation Forum

Of all the factors driving innovation, organisations across a spectrum of industries find three Cs in common— curiosity, commitment and creativity. At the 2021 Clarivate Virtual Innovation Forum for the Middle East, Africa and Russia region which took place in May, speakers, panellists and moderators emphasised these factors and the power they have to drive […]